PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of diametsynBioMed CentralBiomed Central Web Sitesearchsubmit a manuscriptregisterthis articleDiabetology & Metabolic SyndromeJournal Front Page
 
Diabetol Metab Syndr. 2010; 2: 57.
Published online 2010 August 25. doi:  10.1186/1758-5996-2-57
PMCID: PMC2933610

Correction: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus

Correction

Since publication of our article [1], we have noticed that amendments to the second sentence of the "Study Design" section are required as this should read as follows:

"Approved by the local ethics committee, patient enrolment was restricted to the following patients: those aged 18 years and greater and taking immediate release metformin alone or in combination with other oral agents, those excluded had symptoms of poor diabetes control, were pregnant, had serum creatinine levels >1.3 mg/dL (female) or 1.4 mg/dL (male), nephropathy, evidence of hepatic disease or history of alcohol abuse."

We apologize for any inconvenience or confusion that this may have caused.

References

  • Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:16. doi: 10.1186/1758-5996-2-16. [PMC free article] [PubMed] [Cross Ref]

Articles from Diabetology & Metabolic Syndrome are provided here courtesy of BioMed Central